发布求助
文献互助 智能选刊 最新文献

Drug Discovery Today最新文献

筛选
英文 中文
Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies KRAS突变癌症的代谢重编程：已证实的靶向弱点和潜在的治疗策略。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-29 DOI: 10.1016/j.drudis.2024.104220
Ruilin Wu , Hong Zhu , Qiaojun He , Tao Yuan , Bo Yang
{"title":"Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies","authors":"Ruilin Wu ,&nbsp;Hong Zhu ,&nbsp;Qiaojun He ,&nbsp;Tao Yuan ,&nbsp;Bo Yang","doi":"10.1016/j.drudis.2024.104220","DOIUrl":"10.1016/j.drudis.2024.104220","url":null,"abstract":"<div><div><em>Kras</em> (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), one of the most frequently mutated oncogenes in the human genome, is considered ‘untargetable’. Although specific KRAS<sup>G12C</sup> inhibitors have been developed, their overall impact is limited, highlighting the need for further research on targeting KRAS-mutant cancers. Metabolic abnormalities are key hallmarks of cancer, with KRAS-driven tumors exhibiting traits like glycolysis upregulation, glutamine addiction, lipid droplet accumulation, highly active macropinocytosis, and metabolic reprogramming-associated tumor microenvironment remodeling. Targeting these unique metabolic characteristics offers a promising strategy for new cancer treatments. This review summarizes recent advances in our understanding of the metabolic network in KRAS-mutated tumor cells, discusses potential targetable vulnerabilities, and outlines clinical developments in relevant therapies, while also addressing challenges to improve strategies against these aggressive cancers.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104220"},"PeriodicalIF":6.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142556738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Green synthesis of metal nanocarriers: A perspective for targeting glioblastoma 金属纳米载体的绿色合成：靶向胶质母细胞瘤的前景。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-29 DOI: 10.1016/j.drudis.2024.104219
Taskeen F. Docrat , Ali O.E. Eltahir , Ahmed A. Hussein , Jeanine.L. Marnewick
{"title":"Green synthesis of metal nanocarriers: A perspective for targeting glioblastoma","authors":"Taskeen F. Docrat ,&nbsp;Ali O.E. Eltahir ,&nbsp;Ahmed A. Hussein ,&nbsp;Jeanine.L. Marnewick","doi":"10.1016/j.drudis.2024.104219","DOIUrl":"10.1016/j.drudis.2024.104219","url":null,"abstract":"<div><div>Glioblastoma, the most aggressive brain cancer, is challenging to treat owing to the difficulty of crossing the blood–brain barrier, high recurrence rates and significant mortality. This review highlights the potential of green synthesis methods in developing metal nanoparticles (MNPs) as a sustainable solution for drug delivery systems targeting glioblastoma. We explore the unique properties and modes of action of MNPs synthesised through eco-friendly processes by focusing on their bioavailability and precision in brain targeting, and discuss the potential of MNPs to target glioblastoma at the molecular level. Integrating green synthesis into cancer therapeutics represents a novel paradigm shift towards treatments with higher efficacy and lower environmental impact, offering hope in the fight against glioblastoma.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104219"},"PeriodicalIF":6.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to nurture natural products to create new therapeutics: Strategic innovations and molecule-to-medicinal insights into therapeutic advancements 如何培育天然产品以创造新疗法：战略创新和从分子到药物的治疗进展见解。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-29 DOI: 10.1016/j.drudis.2024.104221
Ayan Acharya, Mithilesh Nagpure, Nibedita Roy, Vaibhav Gupta, Soumyadeep Patranabis, Sankar K. Guchhait
{"title":"How to nurture natural products to create new therapeutics: Strategic innovations and molecule-to-medicinal insights into therapeutic advancements","authors":"Ayan Acharya,&nbsp;Mithilesh Nagpure,&nbsp;Nibedita Roy,&nbsp;Vaibhav Gupta,&nbsp;Soumyadeep Patranabis,&nbsp;Sankar K. Guchhait","doi":"10.1016/j.drudis.2024.104221","DOIUrl":"10.1016/j.drudis.2024.104221","url":null,"abstract":"<div><div>Natural products (NPs) are privileged structures interacting with biomacromolecular targets and exhibiting biological effects important for human health. In this review, we have presented NP-inspired strategic innovations that are promising for addressing preclinical and clinical challenges. An analysis of ‘molecule-to-medicinal’ properties for improvement of P3 and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles has been illustrated. The strategies include chemical evolution through knowledge of structure–medicinal properties, truncation of NPs to avoid molecular obesity, pseudo-NPs, selection of common structural features of NPs, medicinophore installation, scaffold hopping, and induced proximity. Molecule-to-medicinal property analysis can guide the development of ‘nature-to-new’ chemical therapeutics. Coupled with scientific advances and innovations in instrumentation, these strategies hold great potential for enhancing drug design and discovery.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104221"},"PeriodicalIF":6.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142556737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevating life science R&D success with AI: a framework 利用人工智能提升生命科学研发的成功率：一个框架。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-22 DOI: 10.1016/j.drudis.2024.104211
Ben Sidders
{"title":"Elevating life science R&D success with AI: a framework","authors":"Ben Sidders","doi":"10.1016/j.drudis.2024.104211","DOIUrl":"10.1016/j.drudis.2024.104211","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104211"},"PeriodicalIF":6.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs from drugs: New chemical insights into a mature concept 从药物中提取药物：对成熟概念的新化学见解。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-22 DOI: 10.1016/j.drudis.2024.104212
Eloy Lozano Baró , Federica Catti , Carolina Estarellas , Ouldouz Ghashghaei , Rodolfo Lavilla
{"title":"Drugs from drugs: New chemical insights into a mature concept","authors":"Eloy Lozano Baró ,&nbsp;Federica Catti ,&nbsp;Carolina Estarellas ,&nbsp;Ouldouz Ghashghaei ,&nbsp;Rodolfo Lavilla","doi":"10.1016/j.drudis.2024.104212","DOIUrl":"10.1016/j.drudis.2024.104212","url":null,"abstract":"<div><div>Developing new drugs from marketed ones is a well-established and successful approach in drug discovery. We offer a unified view of this field, focusing on the new chemical aspects of the involved approaches: (a) chemical transformation of the original drugs (late-stage modifications, molecular editing), (b) prodrug strategies, and (c) repurposing as a tool to develop new hits/leads. Special focus is placed on the molecular structure of the drugs and their synthetic feasibility. The combination of experimental advances and new computational approaches, including artificial intelligence methods, paves the way for the evolution of the drugs from drugs concept.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104212"},"PeriodicalIF":6.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The identification of essential cellular genes is critical for validating drug targets 鉴定重要的细胞基因对于验证药物靶点至关重要。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-18 DOI: 10.1016/j.drudis.2024.104215
Ting Xu , Shuang Wang , Tingting Ma , Yawen Dong , Charles R. Ashby Jr , Ge-Fei Hao
{"title":"The identification of essential cellular genes is critical for validating drug targets","authors":"Ting Xu ,&nbsp;Shuang Wang ,&nbsp;Tingting Ma ,&nbsp;Yawen Dong ,&nbsp;Charles R. Ashby Jr ,&nbsp;Ge-Fei Hao","doi":"10.1016/j.drudis.2024.104215","DOIUrl":"10.1016/j.drudis.2024.104215","url":null,"abstract":"<div><div>Accurately identifying biological targets is crucial for advancing treatment options. Essential genes, vital for cell or organism survival, hold promise as potential drug targets in disease treatment. Although many studies have sought to identify essential genes as therapeutic targets in medicine and bioinformatics, systematic reviews on their relationship with drug targets are relatively rare. This work presents a comprehensive analysis to aid in identifying essential genes as potential targets for drug discovery, encompassing their relevance, identification methods, successful case studies, and challenges. This work will facilitate the identification of essential genes as therapeutic targets, thereby boosting new drug development.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104215"},"PeriodicalIF":6.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ex vivo permeability study of poorly soluble drugs across gastrointestinal membranes: acceptor compartment media composition 差溶性药物通过胃肠道膜的体内外渗透性研究：受体区介质成分。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-18 DOI: 10.1016/j.drudis.2024.104214
Andrejs Sitovs , Valentyn Mohylyuk
{"title":"Ex vivo permeability study of poorly soluble drugs across gastrointestinal membranes: acceptor compartment media composition","authors":"Andrejs Sitovs ,&nbsp;Valentyn Mohylyuk","doi":"10.1016/j.drudis.2024.104214","DOIUrl":"10.1016/j.drudis.2024.104214","url":null,"abstract":"<div><div><em>Ex vivo</em> drug permeability testing across gastrointestinal (GI) membranes is crucial in drug discovery and oral drug delivery. It is a reliable method for drugs with good solubility, but it poses challenges for poorly soluble drugs, which are common in development pipelines today. Although enabling formulations increase the apparent solubility in the GI compartment (dissolution vessel or permeation chamber’s donor compartment), maintaining solubilized drug in the acceptor compartment during <em>ex vivo</em> testing remains largely unresolved. This review compiles and critically evaluates the diverse compositions of acceptor media used in <em>ex vivo</em> permeability studies for poorly soluble drugs, highlighting this significant yet underexplored aspect of pharmaceutical science. An algorithm is proposed for selecting solubility-enhancing additives for the acceptor media in <em>ex vivo</em> permeability studies of poorly soluble drugs.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104214"},"PeriodicalIF":6.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Challenges and Opportunities in Clinical Trial Diversity 临床试验多样性的挑战与机遇 对医疗系统的不信任是招募人员的一大障碍。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-18 DOI: 10.1016/j.drudis.2024.104210
Lisa Bailey (Managing Director Insights and Head of DEI Strategy, Trinity Life Sciences)
{"title":"The Challenges and Opportunities in Clinical Trial Diversity","authors":"Lisa Bailey (Managing Director Insights and Head of DEI Strategy, Trinity Life Sciences)","doi":"10.1016/j.drudis.2024.104210","DOIUrl":"10.1016/j.drudis.2024.104210","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104210"},"PeriodicalIF":6.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role 欧盟人用药品监管中的环境风险评估：利益相关者对其当前和未来作用的观点分析。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-18 DOI: 10.1016/j.drudis.2024.104213
Jim F. Zinken , Anna M.G. Pasmooij , Antwan G.H. Ederveen , Jarno Hoekman , Lourens T. Bloem
{"title":"Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role","authors":"Jim F. Zinken ,&nbsp;Anna M.G. Pasmooij ,&nbsp;Antwan G.H. Ederveen ,&nbsp;Jarno Hoekman ,&nbsp;Lourens T. Bloem","doi":"10.1016/j.drudis.2024.104213","DOIUrl":"10.1016/j.drudis.2024.104213","url":null,"abstract":"<div><div>An environmental risk assessment (ERA) is mandatory for all applications for marketing authorisation of medicines in the European Union (EU). We investigated stakeholder perspectives on the role of the ERA in EU regulation of medicines for human use. We discuss the current position of the ERA and the current conduct and assessment of the ERA, such as the required expertise, data, and studies, its applicability to generic drugs, and its use in regulatory decision-making. We also discuss future perspectives, including extension of the ERA to cover antimicrobial resistance, improved risk mitigation, impact on ‘over-the-counter’ (OTC) status, and incorporation into reimbursement considerations.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104213"},"PeriodicalIF":6.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases 开启治疗前沿：利用人工智能发现治疗神经退行性疾病的药物。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2024-10-18 DOI: 10.1016/j.drudis.2024.104216
Bilal Nehmeh , Joseph Rebehmed , Riham Nehmeh , Robin Taleb , Elias Akoury
{"title":"Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases","authors":"Bilal Nehmeh ,&nbsp;Joseph Rebehmed ,&nbsp;Riham Nehmeh ,&nbsp;Robin Taleb ,&nbsp;Elias Akoury","doi":"10.1016/j.drudis.2024.104216","DOIUrl":"10.1016/j.drudis.2024.104216","url":null,"abstract":"<div><div>Neurodegenerative diseases (NDs) pose serious healthcare challenges with limited therapeutic treatments and high social burdens. The integration of artificial intelligence (AI) into drug discovery has emerged as a promising approach to address these challenges. This review explores the application of AI techniques to unravel therapeutic frontiers for NDs. We examine the current landscape of AI-driven drug discovery and discuss the potentials of AI in accelerating the identification of novel therapeutic targets on ND research and drug development, optimization of drug candidates, and expediating personalized medicine approaches. Finally, we outline future directions and challenges in harnessing AI for the advancement of therapeutics in this critical area by emphasizing the importance of interdisciplinary collaboration and ethical considerations.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 12","pages":"Article 104216"},"PeriodicalIF":6.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信